Tyme Technologies Inc (NASDAQ:TYME) shares saw unusually-high trading volume on Tuesday . Approximately 729,300 shares were traded during trading, an increase of 140% from the previous session’s volume of 303,556 shares.The stock last traded at $2.63 and had previously closed at $2.47.
TYME has been the subject of a number of research reports. Canaccord Genuity restated a “buy” rating on shares of Tyme Technologies in a research note on Friday, June 15th. BidaskClub cut shares of Tyme Technologies from a “hold” rating to a “sell” rating in a research note on Wednesday, July 18th. Finally, Zacks Investment Research upgraded shares of Tyme Technologies from a “hold” rating to a “buy” rating and set a $2.75 target price for the company in a research note on Friday, August 10th. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $7.31.
The company has a market capitalization of $266.23 million, a PE ratio of -12.81 and a beta of 0.22.
Several hedge funds and other institutional investors have recently bought and sold shares of TYME. Family Management Corp lifted its stake in shares of Tyme Technologies by 27.3% during the 1st quarter. Family Management Corp now owns 140,000 shares of the company’s stock worth $312,000 after buying an additional 30,000 shares during the last quarter. Farallon Capital Management LLC bought a new position in Tyme Technologies during the first quarter worth about $3,190,000. Millennium Management LLC increased its position in Tyme Technologies by 551.5% during the first quarter. Millennium Management LLC now owns 1,551,315 shares of the company’s stock worth $3,459,000 after acquiring an additional 1,313,190 shares during the period. Perkins Capital Management Inc. increased its position in Tyme Technologies by 330.0% during the second quarter. Perkins Capital Management Inc. now owns 101,050 shares of the company’s stock worth $319,000 after acquiring an additional 77,550 shares during the period. Finally, Rhumbline Advisers bought a new position in Tyme Technologies during the second quarter worth about $110,000. Institutional investors own 11.13% of the company’s stock.
Tyme Technologies Company Profile (NASDAQ:TYME)
Tyme Technologies, Inc, a clinical-stage biotechnology company, develops novel cancer therapeutics. It is developing SM-88, a combination therapy based on dysfunctional metyrosine derivatives in Phase II development for metastatic pancreatic cancer and biomarker-recurrent prostate cancer. The company was founded in 2011 and is headquartered in New York, New York.
See Also: How is a Moving Average Calculated?
Receive News & Ratings for Tyme Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyme Technologies and related companies with MarketBeat.com's FREE daily email newsletter.